Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635 | ISIN: INE0DK501011 | Industry: Pharmaceuticals
| Expensive Performer

206.3300 -1.75 (-0.84%)

NSE Jun 06, 2025 15:31 PM

32.99% Fall from 52W High

Volume: 2.9M

Piramal Pharma Ltd.

25 Sep 2024

206.33

-0.84%

Geared to drive robust operating leverage across segments

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment.

Piramal Pharma Ltd. has gained 41.42% in the last 1 Year